Printer Friendly

India : Alembic Pharmaceuticals receives USFDA Approval for Bromfenac Ophthalmic Solution 0.09%.

Alembic Pharmaceuticals Limited announced that the Company has received approval from the US Food & Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) Bromfenac Oph0thalmic Solution 0.09%. The approved ANDA is therapeutically equivalent to the reference listed drug (RLD), Bromday Ophthalmic Solution, 0.09%, of Bausch & Lomb Incorporated (Bausch & Lomb). Bromfenac Ophthalmic Solution 0.09% is indicated for the treatment of postoperative inflammation and reduction of ocular pain in patients who have undergone cataract surgery.

Bromfenac Ophthalmic Solution 0.09% has an estimated market size of US$ 6 million for twelve months ending December 2018 according to IQVIA.

Alembic now has a total of 96 ANDA approvals 84 final approvals and 12 tentative approvals) from USFDA.

[c] 2019 Al Bawaba ( Provided by SyndiGate Media Inc. ( ).

COPYRIGHT 2019 SyndiGate Media Inc.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2019 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Mena Report
Geographic Code:9INDI
Date:Jun 29, 2019
Previous Article:Israel,United States : Israel Railways Will Boost Passenger Safety and Operational Efficiency with New Work Group Communication Service from Motorola...
Next Article:India : Alembic Pharmaceuticals receives USFDA Approval for Oseltamivir Phosphate Capsules USP. 30 mq (base), 45 mq (base), and 75 mq (base).

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters